Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Dana, Shuey"'
Autor:
David Ackley, Joanne Birkebak, Jorg Blumel, Todd Bourcier, Christina de Zafra, Andrew Goodwin, Wendy Halpern, Danuta Herzyk, Sven Kronenberg, Robert Mauthe, Jacintha Shenton, Dana Shuey, Ronald L. Wange
Publikováno v:
Regulatory toxicology and pharmacology : RTP. 138
The nonhuman primate (NHP) has always been a limited resource for pharmaceutical research with ongoing efforts to conserve. This is due to their inherent biological properties, the growth in biotherapeutics and other modalities, and their use in smal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5931fc33f2ffe38581252e72ca007cdc
https://pubmed.ncbi.nlm.nih.gov/36586472
https://pubmed.ncbi.nlm.nih.gov/36586472
Autor:
Qian Wang, Sybil O'Connor, Alan Roberts, Brian W. Metcalf, Leslie Hall, Maxim Soloviev, Michael Hansbury, Greg Hollis, Xin He, Matthew C. Stubbs, Niu Shin, Wenqing Yao, Kamna Katiyar, Phillip C.C. Liu, Kathy Wang, Sharon Diamond, Brent Douty, Gengjie Yang, Dana Shuey, Maryanne B. Covington, Paul Collier, Mingming Gao, Patricia Feldman, Peggy Scherle, Timothy Burn, Andrew P. Combs, Yun-Long Li, Lynn Leffet, Robert C. Newton, Paul Waeltz, Holly Koblish, Jin Lu, Swamy Yeleswaram, Yanlong Li, Reid Huber, Robert Collins, Eddy W. Yue
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 374:211-222
The clinical use of first-generation phosphoinositide 3-kinase (PI3K)δ inhibitors in B-cell malignancies is hampered by hepatotoxicity, requiring dose reduction, treatment interruption, and/or discontinuation of therapy. In addition, potential molec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::450ddea425cecfdf40bf1184c7e8c723
https://doi.org/10.1124/jpet.120.265538
https://doi.org/10.1124/jpet.120.265538
Autor:
Junguo Zhou, Paul Butler, Meredith Crosby, Laura Aschenbrenner, Jim Blank, Jonathan G. Moggs, Vincent L. Reynolds, Kyle L. Kolaja, Derek D. Best, Dana Shuey, Matthew M. Abernathy, Terry R. Van Vleet, Chelsea Snyder, Patricia A. Escobar, Timothy K. Hart, Laura Custer
Publikováno v:
Regulatory toxicology and pharmacology : RTP. 117
Pharmaceutic products designed to perturb the function of epigenetic modulators have been approved by regulatory authorities for treatment of advanced cancer. While the predominant effort in epigenetic drug development continues to be in oncology, no
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d0c03ba3f1ed7746ed6a53efdd5ecdd
https://pubmed.ncbi.nlm.nih.gov/32911461
https://pubmed.ncbi.nlm.nih.gov/32911461
Autor:
Niu, Shin, Matthew, Stubbs, Holly, Koblish, Eddy W, Yue, Maxim, Soloviev, Brent, Douty, Kathy He, Wang, Qian, Wang, Mingming, Gao, Patricia, Feldman, Gengjie, Yang, Leslie, Hall, Michael, Hansbury, Sybil, O'Connor, Lynn, Leffet, Robert, Collins, Kamna, Katiyar, Xin, He, Paul, Waeltz, Paul, Collier, Jin, Lu, Yun-Long, Li, Yanlong, Li, Phillip C C, Liu, Timothy, Burn, Maryanne, Covington, Sharon, Diamond, Dana, Shuey, Alan, Roberts, Swamy, Yeleswaram, Greg, Hollis, Brian, Metcalf, Wenqing, Yao, Reid, Huber, Andrew, Combs, Robert, Newton, Peggy, Scherle
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 374(1)
The clinical use of first-generation phosphoinositide 3-kinase (PI3K)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::14a526e7b4c814d8f260a1bead68f92f
https://pubmed.ncbi.nlm.nih.gov/32345620
https://pubmed.ncbi.nlm.nih.gov/32345620
Autor:
Dana Shuey
Publikováno v:
Birth Defects Research. 111:627-629
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c9501e717d8f60d4b26413853bef842
https://doi.org/10.1002/bdr2.1527
https://doi.org/10.1002/bdr2.1527
Autor:
Sharon Diamond, Kamna Katiyar, Qian Wang, Andrew P. Combs, Holly Koblish, Gengjie Yang, Jordan S. Fridman, Maryanne B. Covington, Gregory Hollis, Yanlong Li, Jun Li, Swamy Yeleswaram, Xin He, Reid Huber, Yun-Long Li, Lynn Leffet, Mark Rupar, Kathy Wang, Dana Shuey, Wenqing Yao, Leslie Hall, Maxim Soloviev, Kevin Bowman, Robert C. Newton, Mike Liu, Margaret F. Favata, Peggy Scherle, Timothy Burn, Kris Vaddi, Beth Rumberger, Song Mei, Niu Shin
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 364:120-130
Phosphatidylinositol 3-kinase delta (PI3Kδ) is a critical signaling molecule in B cells and is considered a target for development of therapies against various B cell malignancies. INCB040093 is a novel PI3Kδ small-molecule inhibitor and has demons
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::95263249a805825553343b41c10e5cf4
https://doi.org/10.1124/jpet.117.244947
https://doi.org/10.1124/jpet.117.244947
Autor:
Lisa Beilke, Lidiya Stavitskaya, Penny Leavitt, Alexander Amberg, Donald P. Quigley, Angela White, James Harvey, Naomi L. Kruhlak, Raymond Kemper, Craig Zwickl, Claire L. Neilan, Ernst Ahlberg, Kevin P. Cross, Joerg Wichard, Glenn J. Myatt, Dana Shuey, Hans-Peter Spirkl, Michelle O. Kenyon, Masamitsu Honma, Robert A. Jolly, David Bower, Elisabeth Joossens, Jacky Van Gompel, Lara Kuhnke, Laura Custer, Kevin A. Ford, Russell T. Naven, Andrew Teasdale
Publikováno v:
Regulatory Toxicology and Pharmacology. 77:1-12
Statistical-based and expert rule-based models built using public domain mutagenicity knowledge and data are routinely used for computational (Q)SAR assessments of pharmaceutical impurities in line with the approach recommended in the ICH M7 guidelin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32e433017dbcf484af3c46d7c78df622
https://doi.org/10.1016/j.yrtph.2016.02.003
https://doi.org/10.1016/j.yrtph.2016.02.003
Autor:
Niu, Shin, Yun-Long, Li, Song, Mei, Kathy He, Wang, Leslie, Hall, Kamna, Katiyar, Qian, Wang, Gengjie, Yang, Beth, Rumberger, Lynn, Leffet, Xin, He, Mark, Rupar, Kevin, Bowman, Margaret, Favata, Jun, Li, Mike, Liu, Yanlong, Li, Maryanne, Covington, Holly, Koblish, Maxim, Soloviev, Dana, Shuey, Timothy, Burn, Sharon, Diamond, Jordan, Fridman, Andrew, Combs, Wenqing, Yao, Swamy, Yeleswaram, Gregory, Hollis, Kris, Vaddi, Reid, Huber, Robert, Newton, Peggy, Scherle
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 364(1)
Phosphatidylinositol 3-kinase delta (PI3K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::baeaea6f34f538a85fee066a6746ba98
https://pubmed.ncbi.nlm.nih.gov/29127109
https://pubmed.ncbi.nlm.nih.gov/29127109
Publikováno v:
Regulatory toxicology and pharmacology : RTP. 81
Ruxolitinib is a selective and potent inhibitor of Janus kinase (JAK) 1 and JAK2. It is approved for the treatment of patients with intermediate or high-risk myelofibrosis, or those with polycythemia vera who have had an inadequate response to or are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15aeccc94f71845be96c5cc65a318a7b
https://pubmed.ncbi.nlm.nih.gov/27647628
https://pubmed.ncbi.nlm.nih.gov/27647628
Autor:
Alan Roberts, Sang Hyun Lee, Sybil O'Connor, Swamy Yeleswaram, Liangxing Wu, Alexander Margulis, Wenqing Yao, Gengjie Yang, Valerie Roman, Bruce Ruggeri, Krista Burke, Yan Zhang, Kevin Bowman, Dana Shuey, Yan-ou Yang, Sharon Diamond, Reid Huber, Gregory Hollis, Maxim Soloviev, Richard Wynn, Peggy Scherle, Timothy Burn
Publikováno v:
Blood. 128:2472-2472
Sickle cell disease (SCD) is an autosomal recessive genetic disorder caused by a point mutation in the human β-globin gene. Patients harboring this mutation can exhibit long-chain polymers of hemoglobin and sickle-shaped red blood cells, and suffer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a7c84a7e161dd26bdf2bf26be7a710ce
https://doi.org/10.1182/blood.v128.22.2472.2472
https://doi.org/10.1182/blood.v128.22.2472.2472